A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy |
| |
| Authors: | Chris L Bryson MD Bruce M Psaty MD PhD |
| |
| Institution: | (1) VA Puget Sound HSR&D, MS-152 1660S. Columbian Way Department of Veterans Affairs Medical Center, Seattle, WA 98108-1597, USA;(2) Cardiovascular Health Research Unit Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle Cardiovascular Health Research Unit, 1730 Minor Ave. #1360, Seattle, WA 98101, USA |
| |
| Abstract: | Background Doxazosin and its role as an antihypertensive agent have come under recent scrutiny as a result of the early termination of that treatment arm in ALLHAT. It is unclear why the cardiovascular (CV) event rate in this randomized, controlled trial (RCT), especially heart failure, is higher in those treated with a doxazosin-based regimen than with a chlorthalidone based-regimen. There has been little work in the past to summarize information on peripheral alpha-1 antagonists that may be helpful in evaluating the results of this randomized controlled trial. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
